Early_JJ Detection_NN of_IN Negative_JJ BACTEC_NP MGIT_NP 960_NP Cultures_NP by_IN PCR-Reverse_NP Cross-Blot_NP Hybridization_NP Assay_NP We_PP evaluated_VBD the_DT efficacy_NN of_IN a_DT PCR-reverse_NP cross-blot_NN hybridization_NN assay_NN ,_, a_DT test_NN which_WDT permits_VBZ identification_NN of_IN mycobacteria_NNS by_IN means_NNS of_IN species-specific_JJ probes_NNS and_CC a_DT Mycobacterium-specific_JJ probe_NN ,_, for_IN early_JJ detection_NN of_IN negative_JJ BACTEC_NP MGIT_NP 960_CD mycobacterial_JJ cultures_NNS ._SENT Aliquots_NNS of_IN 549_CD cultures_NNS were_VBD collected_VBN 7_CD days_NNS after_IN the_DT culture_NN media_NNS were_VBD inoculated_VBN with_IN various_JJ clinical_JJ specimens_NNS and_CC tested_VBN with_IN the_DT molecular_JJ assay_NN ._SENT PCR_NP results_NNS were_VBD compared_VBN to_TO those_DT obtained_VBN at_IN the_DT end_NN times_NNS with_IN the_DT BACTEC_NP MGIT_NP 960_CD system_NN ._SENT Of_IN the_DT 549_CD specimens_NNS analyzed_VBD ,_, 484_CD were_VBD found_VBN to_TO be_VB negative_JJ and_CC 64_CD were_VBD found_VBN positive_JJ by_IN both_DT methods_NNS ;_: one_CD specimen_NN ,_, found_VBD to_TO be_VB positive_JJ by_IN the_DT BACTEC_NP MGIT_NP 960_CD system_NN ,_, was_VBD identified_VBN as_IN negative_JJ by_IN the_DT molecular_JJ assay_NN ._SENT In_IN view_NN of_IN its_PP$ high_JJ negative_JJ predictive_JJ value_NN (_( 99.8_CD %_NN )_) ,_, the_DT PCR-reverse_NP cross-blot_NN hybridization_NN assay_NN appears_VBZ to_TO be_VB a_DT valid_JJ tool_NN for_IN early_JJ detection_NN of_IN negative_JJ BACTEC_NP MGIT_NP 960_CD cultures_NNS ._SENT Rapid_JJ ,_, accurate_JJ identification_NN of_IN mycobacterial_JJ species_NNS in_IN clinical_JJ specimens_NNS is_VBZ an_DT essential_JJ step_NN in_IN any_DT strategy_NN aimed_VBN at_IN limiting_VBG the_DT diffusion_NN of_IN infections_NNS caused_VBN by_IN these_DT slow-growing_JJ organisms_NNS ._SENT Conventional_JJ methods_NNS for_IN recovery_NN of_IN mycobacteria_NNS have_VBP been_VBN supported_VBN by_IN other_JJ techniques_NNS ,_, such_JJ as_IN liquid_JJ culture-_NN and_CC molecular_JJ biology-based_JJ systems_NNS ,_, which_WDT can_MD be_VB used_VBN alone_RB or_CC in_IN combination_NN to_TO obtain_VB accurate_JJ results_NNS in_IN a_DT much_RB shorter_JJR period_NN of_IN time_NN ._SENT With_IN the_DT new_JJ BACTEC_NP MGIT_NP 960_NP (_( Becton_NP Dickinson_NP )_) liquid_JJ culture_NN detection_NN system_NN ,_, the_DT presence_NN of_IN mycobacteria_NNS in_IN a_DT clinical_JJ specimen_NN is_VBZ detected_VBN ,_, on_IN average_NN ,_, 2_CD weeks_NNS after_IN inoculation_NN (_( ,_, -_: ,_, ,_, ,_, )_) ._SENT Unfortunately_RB ,_, 6_CD weeks_NNS must_MD pass_VB before_IN a_DT specimen_NN can_MD be_VB reliably_RB declared_VBN to_TO be_VB negative_JJ for_IN mycobacteria_NNS ,_, and_CC this_DT delay_NN may_MD lead_VB to_TO inappropriate_JJ empirical_JJ treatment_NN with_IN antimycobacterial_JJ drugs_NNS ._SENT We_PP evaluated_VBD a_DT PCR-reverse_NP cross-blot_NN hybridization_NN assay_NN ,_, previously_RB developed_VBN for_IN direct_JJ detection_NN and_CC identification_NN of_IN mycobacteria_NNS in_IN clinical_JJ specimens_NNS (_( -_: ,_, )_) ,_, as_IN a_DT potential_JJ predictor_NN of_IN negativity_NN in_IN BACTEC_NP MGIT_NP 960_CD cultures_NNS ,_, and_CC we_PP used_VBD this_DT molecular_JJ assay_NN on_IN aliquots_NNS of_IN BACTEC_NP MGIT_NP 960_CD cultures_NNS 7_CD days_NNS after_IN the_DT culture_NN media_NNS were_VBD inoculated_VBN with_IN various_JJ clinical_JJ specimens_NNS ._SENT Results_NNS were_VBD compared_VBN to_TO those_DT furnished_VBN by_IN the_DT BACTEC_NP MGIT_NP 960_CD instrument_NN at_IN the_DT end_NN of_IN the_DT 6-week_JJ incubation_NN period_NN ._SENT A_DT total_NN of_IN 549_CD respiratory_JJ and_CC nonrespiratory_JJ ,_, consecutively_RB enrolled_VBN clinical_JJ specimens_NNS (_( sputum_NN ,_, 354_CD samples_NNS ;_: bronchoalveolar_JJ lavage_NN fluid_NN ,_, 92_CD samples_NNS ;_: urine_NN ,_, 79_CD samples_NNS ;_: others_NNS [_SYM cerebrospinal_JJ fluid_NN ,_, blood_NN ,_, stool_NN ,_, ascitic_JJ fluid_NN ,_, abscess_NN fluid_NN ,_, and_CC biopsy_NN specimen_NN ]_SYM ,_, 24_CD samples_NNS [_SYM total_NN ]_SYM )_) were_VBD collected_VBN from_IN 549_CD patients_NNS suspected_VBN of_IN having_VBG mycobacterial_JJ infections_NNS ._SENT Most_JJS of_IN these_DT patients_NNS were_VBD hospitalized_VBN in_IN wards_NNS reserved_VBN for_IN hematology_NN and_CC the_DT treatment_NN of_IN infectious_JJ diseases_NNS ._SENT Specimens_NNS from_IN sterile_JJ body_NN sites_NNS were_VBD used_VBN directly_RB to_TO prepare_VB smears_NNS for_IN Ziehl-Neelsen_NP acid-fast_JJ staining_VBG and_CC BACTEC_NP MGIT_NP 960_CD cultures_NNS ._SENT Those_DT from_IN nonsterile_JJ sites_NNS were_VBD digested_VBN and_CC decontaminated_VBN by_IN standard_JJ procedures_NNS ._SENT The_DT supernatant_JJ was_VBD discarded_VBN ,_, the_DT pellet_NN was_VBD suspended_VBN in_IN a_DT sterile_JJ phosphate_NN buffer_NN (_( final_JJ volume_NN ,_, 2_CD ml_NN )_) ,_, and_CC the_DT mixture_NN was_VBD used_VBN for_IN smear_NN and_CC culture_NN preparation_NN ._SENT For_IN each_DT specimen_NN ,_, we_PP prepared_VBD two_CD BACTEC_NP MGIT_NP 960_CD tubes_NNS (_( designated_VBN A_NP and_CC B_NP )_) ,_, each_DT containing_VBG 0.8_CD ml_NN of_IN MGIT_NP oleic_JJ acid-albumin-dextrose-citrate_NN enrichment_NN (_( Becton_NP Dickinson_NP )_) and_CC 0.1_CD ml_NN of_IN antibiotic_JJ mixture_NN MGIT_NP PANTA_NP (_( polimyxin_NP B_NP ,_, nalidixic_JJ acid_NN ,_, trimethoprim_NP ,_, and_CC azlocillin_NN )_) ._SENT The_DT inoculum_NN was_VBD added_VBN (_( 0.5_CD ml/tube_NN )_) ,_, and_CC the_DT tubes_NNS were_VBD incubated_VBN inside_IN the_DT device_NN at_IN 37C_JJ and_CC automatically_RB monitored_VBN for_IN 6_CD weeks_NNS or_CC until_IN an_DT alarm_NN signal_NN indicated_VBD mycobacterial_JJ growth_NN ._SENT In_IN addition_NN ,_, two_CD Lowenstein-Jensen_NP slants_NNS were_VBD inoculated_VBN with_IN 0.25_CD ml_NN of_IN each_DT suspension_NN ,_, incubated_VBN at_IN 37C_JJ for_IN 8_CD weeks_NNS ,_, and_CC inspected_VBD weekly_JJ ._SENT When_WRB the_DT BACTEC_NP MGIT_NP 960_CD system_NN indicated_JJ positivity_NN ,_, the_DT sample_NN was_VBD removed_VBN and_CC subjected_VBN to_TO microscopic_JJ confirmation_NN and_CC species_NN identification_NN of_IN mycobacteria_NNS by_IN the_DT AccuProbe_NP confirmation_NN test_NN (_( Gen-Probe_NP ,_, Inc._NP ,_, San_NP Diego_NP ,_, Calif._NP )_) ,_, hsp65_JJ PCR-restriction_NN enzyme_NN analysis_NN ,_, or_CC conventional_JJ procedures_NNS ._SENT The_DT mycobacterial_JJ colonies_NNS grown_VBN on_IN the_DT Lowenstein-Jensen_NP slants_NNS were_VBD identified_VBN as_IN described_VBN above_IN ._SENT reverse_JJ cross-blot_NN hybridization_NN assay_NN ._SENT :_: On_IN the_DT seventh_JJ day_NN of_IN incubation_NN ,_, a_DT 1-ml_JJ aliquot_NN from_IN each_DT A-tube_NP culture_NN was_VBD aseptically_RB collected_VBN for_IN testing_NN with_IN the_DT PCR-reverse_NP cross-blot_NN hybridization_NN assay_NN (_( see_VB below_IN )_) and_CC the_DT remainder_NN of_IN each_DT culture_NN was_VBD reincubated_VBN for_IN 5_CD more_JJR weeks_NNS (_( total_JJ incubation_NN ,_, 6_CD weeks_NNS [_SYM MGIT_JJ end_NN time_NN ]_SYM )_) ._SENT The_DT B_NP tubes_NNS remained_VBD undisturbed_JJ for_IN 6_CD weeks_NNS after_IN inoculation_NN (_( or_CC until_IN mycobacterial_JJ growth_NN was_VBD detected_VBN by_IN the_DT BACTEC_NP MGIT_NP 960_CD system_NN )_) ._SENT The_DT PCR-reverse_NP cross-blot_NN hybridization_NN assay_NN was_VBD carried_VBN out_RP as_IN previously_RB described_VBN ._SENT The_DT PCR_NP products_NNS were_VBD then_RB analyzed_VBN in_IN a_DT reverse_JJ cross-blot_NN hybridization_NN assay_NN with_IN probes_NNS specific_JJ for_IN the_DT genus_NN Mycobacterium_NN and_CC the_DT following_VBG mycobacterial_JJ species_NNS :_: M._NP tuberculosis_NN complex_NN ,_, M._NP avium_NN ,_, M._NP intracellulare_NP ,_, M._NP smegmatis_NP ,_, M._NP marinum_NP (_( or_CC M._NP ulcerans_NNS )_) ,_, M._NP kansasii_NP ,_, M._NP xenopi_NP ,_, M._NP triplex_JJ ,_, M._NP malmoense_NN (_( or_CC M._NP szulgai_NP )_) ,_, M._NP gordonae_NNS ,_, M._NP genavense_NN ,_, M._NP fortuitum_NN ,_, and_CC M._NP chelonae_NNS ._SENT The_DT hybridized_VBN PCR_NP products_NNS were_VBD detected_VBN by_IN incubation_NN with_IN streptavidin-alkaline_NN phosphatase_NN and_CC a_DT color_NN substrate_NN ._SENT At_IN the_DT MGIT_NP end_NN point_NN ,_, BACTEC_NP MGIT_NP 960_CD results_NNS for_IN tubes_NNS A_NP and_CC B_NP were_VBD compared_VBN to_TO those_DT of_IN the_DT PCR_NP assay_NN ._SENT If_IN there_EX was_VBD any_DT discordance_NN ,_, both_CC of_IN the_DT cultures_NNS (_( tubes_NNS A_NP and_CC B_NP )_) of_IN the_DT specimen_NN in_IN question_NN were_VBD subjected_VBN to_TO acid-fast_JJ microscopic_JJ examination_NN and_CC PCR-reverse_JJ cross-blot_NN hybridization_NN ._SENT As_IN shown_VBN in_IN Table_NP ,_, the_DT BACTEC_NP MGIT_NP 960_CD system_NN detected_VBD mycobacterial_JJ growth_NN in_IN 65_CD of_IN 549_CD (_( 11.8_CD %_NN )_) specimens_NNS (_( mean_JJ time_NN to_TO detection_NN ,_, 11.8_CD days_NNS ;_: range_NN ,_, 8_CD to_TO 27_CD days_NNS )_) ._SENT The_DT same_JJ recovery_NN rate_NN was_VBD obtained_VBN on_IN Lowenstein-Jensen_NP solid_JJ medium_NN (_( data_NNS not_RB shown_VBN )_) ._SENT At_IN the_DT end_NN of_IN the_DT 6-week_JJ incubation_NN ,_, the_DT remaining_VBG 484_CD specimens_NNS (_( 88.2_CD %_NN )_) were_VBD negative_JJ ._SENT In_IN the_DT PCR-reverse_NP cross-blot_NN hybridization_NN assay_NN (_( performed_VBN on_IN 7-day_JJ MGIT_NP cultures_NNS )_) ,_, 485_CD specimens_NNS (_( 88.4_CD %_NN )_) were_VBD negative_JJ and_CC 64_CD (_( 11.6_CD %_NN )_) were_VBD positive_JJ ._SENT For_IN the_DT 64_CD specimens_NNS found_VBN to_TO be_VB positive_JJ by_IN both_DT methods_NNS ,_, the_DT PCR_NP products_NNS hybridized_VBN with_IN the_DT probe_NN specific_JJ for_IN M._NP tuberculosis_NN (_( 58_CD specimens_NNS )_) or_CC with_IN the_DT probe_NN specific_JJ for_IN M._NP avium_NN (_( 6_CD specimens_NNS )_) ,_, and_CC these_DT results_NNS were_VBD fully_RB concordant_JJ with_IN the_DT identification_NN data_NNS obtained_VBN with_IN the_DT other_JJ methods_NNS used_VBD ._SENT The_DT sensitivity_NN ,_, specificity_NN ,_, and_CC positive_JJ and_CC negative_JJ predictive_JJ values_NNS of_IN the_DT PCR-reverse_NP cross-blot_NN hybridization_NN assay_NN ,_, compared_VBN to_TO those_DT for_IN the_DT BACTEC_NP MGIT_NP 960_CD system_NN ,_, were_VBD 100_CD %_NN for_IN respiratory_JJ tract_NN specimens_NNS and_CC only_RB slightly_RB lower_JJR for_IN the_DT other_JJ specimens_NNS tested_VBD ._SENT Overall_RB ,_, the_DT assay_NN was_VBD characterized_VBN by_IN high_JJ sensitivity_NN (_( 98.4_CD %_NN )_) and_CC a_DT negative_JJ predictive_JJ value_NN of_IN 99.8_CD %_NN ._SENT The_DT only_JJ case_NN of_IN discordant_JJ results_NNS was_VBD that_IN of_IN a_DT urine_NN specimen_NN that_WDT proved_VBD to_TO be_VB negative_JJ in_IN the_DT molecular_JJ assay_NN ._SENT After_IN 6_CD weeks_NNS of_IN incubation_NN ,_, culture_NN tube_NN A_DT of_IN this_DT specimen_NN was_VBD also_RB declared_VBN to_TO be_VB negative_JJ by_IN the_DT BACTEC_NP MGIT_NP 960_CD detection_NN system_NN ,_, and_CC when_WRB contents_NNS of_IN this_DT tube_NN were_VBD subjected_VBN to_TO PCR-reverse_NP cross-blot_NN hybridization_NN at_IN the_DT end_NN time_NN ,_, no_DT hybridization_NN occurred_VBD with_IN any_DT of_IN the_DT probes_NNS and_CC the_DT microscopic_JJ examination_NN failed_VBD to_TO reveal_VB any_DT evidence_NN of_IN acid-fast_JJ bacilli_NNS ._SENT In_IN contrast_NN ,_, 18_CD days_NNS after_IN inoculation_NN ,_, M._NP gordonae_NNS was_VBD isolated_VBN from_IN the_DT corresponding_JJ B_NP culture_NN ,_, which_WDT was_VBD positive_JJ for_IN the_DT same_JJ microorganism_NN in_IN the_DT molecular_JJ assay_NN ._SENT In_IN all_DT probability_NN ,_, this_DT result_NN is_VBZ a_DT reflection_NN of_IN a_DT paucity_NN of_IN mycobacteria_NNS in_IN the_DT original_JJ clinical_JJ specimen_NN ._SENT Despite_IN clinical_JJ signs_NNS and_CC symptoms_NNS of_IN mycobacterial_JJ infection_NN ,_, the_DT number_NN of_IN bacilli_NNS eliminated_VBN can_MD be_VB quite_RB low_JJ ,_, and_CC this_DT factor_NN is_VBZ often_RB responsible_JJ for_IN false_JJ negativity_NN ,_, even_RB with_IN highly_RB sensitive_JJ detection_NN methods_NNS ._SENT The_DT fact_NN that_IN the_DT PCR-reverse_NP cross-blot_NN hybridization_NN assay_NN incorrectly_RB identified_VBD this_DT urine_NN specimen_NN as_IN negative_JJ for_IN mycobacteria_NNS is_VBZ not_RB a_DT reflection_NN of_IN a_DT lack_NN of_IN sensitivity_NN --_: -the_NN assay_NN 's_POS sensitivity_NN is_VBZ ,_, on_IN the_DT contrary_NN ,_, known_VBN to_TO be_VB quite_RB high_JJ --_: -but_NN rather_RB an_DT artifact_NN of_IN the_DT specimen_NN 's_VBZ having_VBG been_VBN divided_VBN and_CC cultured_VBN in_IN duplicate_NN for_IN control_NN purposes_NNS ._SENT Another_DT possible_JJ explanation_NN for_IN this_DT disagreement_NN between_IN the_DT methods_NNS is_VBZ that_IN M._NP gordonae_NNS was_VBD a_DT contaminant_NN in_IN this_DT case_NN ,_, not_RB a_DT clinically_RB significant_JJ isolate_NN ,_, and_CC the_DT PCR-reverse_NP cross-blot_NN hybridization_NN assay_NN failed_VBD to_TO detect_VB it_PP because_IN the_DT A_NP culture_NN either_CC was_VBD not_RB contaminated_VBN or_CC was_VBD not_RB sufficiently_RB contaminated_VBN with_IN the_DT organism_NN for_IN it_PP to_TO be_VB detected_VBN ._SENT The_DT BACTEC_NP MGIT_NP 960_CD automated_JJ detection_NN system_NN can_MD be_VB a_DT great_JJ time-saver_NN in_IN laboratories_NNS that_WDT process_VBP a_DT high_JJ number_NN of_IN specimens_NNS for_IN detection_NN of_IN mycobacterial_JJ species_NNS ._SENT Our_PP$ objective_NN in_IN the_DT present_JJ study_NN was_VBD to_TO evaluate_VB the_DT efficacy_NN of_IN a_DT PCR-reverse_NP cross-blot_NN hybridization_NN assay_NN as_IN an_DT adjunct_NN to_TO the_DT BACTEC_NP MGIT_NP 960_CD culture_NN detection_NN system_NN for_IN more_JJR rapid_JJ identification_NN of_IN negative_JJ clinical_JJ specimens_NNS ._SENT Performed_VBN on_IN MGIT_NP cultures_NNS after_IN only_RB 7_CD days_NNS of_IN incubation_NN ,_, the_DT PCR-based_JJ assay_NN correctly_RB revealed_VBD the_DT absence_NN of_IN mycobacteria_NNS in_IN all_DT 484_CD specimens_NNS that_WDT were_VBD reported_VBN to_TO be_VB negative_JJ by_IN the_DT automated_JJ detection_NN system_NN after_IN the_DT full_JJ 6-week_JJ period_NN of_IN incubation_NN ._SENT The_DT assay_NN was_VBD equally_RB effective_JJ in_IN identifying_VBG positive_JJ specimens_NNS ,_, and_CC species_NN identification_NN data_NNS were_VBD 100_CD %_NN concordant_JJ with_IN the_DT results_NNS of_IN the_DT AccuProbe_NP culture_NN confirmation_NN test_NN ,_, the_DT hsp65_JJ PCR-restriction_NN enzyme_NN analysis_NN ,_, and_CC conventional_JJ procedures_NNS for_IN mycobacterial_JJ identification_NN ._SENT PCR-reverse_JJ cross-blot_NN hybridization_NN is_VBZ economical_JJ enough_RB to_TO be_VB used_VBN routinely_RB (_( $1.50/specimen_NNS )_) ,_, and_CC in_IN our_PP$ opinion_NN ,_, its_PP$ cost_NN is_VBZ more_JJR than_IN offset_VBN by_IN the_DT potential_JJ savings_NNS allowed_VBN by_IN earlier_JJR reporting_NN (_( e.g._FW ,_, the_DT cost_NN of_IN unnecessary_JJ antimycobacterial_JJ therapy_NN )_) ._SENT Naturally_RB ,_, our_PP$ data_NNS need_VBP to_TO be_VB confirmed_VBN by_IN additional_JJ studies_NNS ,_, but_CC use_VB of_IN the_DT PCR-reverse_NP cross-blot_NN hybridization_NN assay_NN with_IN the_DT BACTEC_NP MGIT_NP 960_CD system_NN seems_VBZ to_TO be_VB a_DT reliable_JJ approach_NN to_TO accelerating_VBG the_DT assessment_NN and_CC ,_, in_IN particular_JJ ,_, the_DT exclusion_NN of_IN suspected_JJ mycobacterial_JJ infections_NNS ._SENT TABLE_NN 1_CD |_SYM Results_NNS of_IN the_DT PCR-reverse_NP cross-blot_NN hybridization_NN assay_NN and_CC the_DT BACTEC_NP MGIT_NP 960_CD system_NN for_IN 549_CD clinical_JJ specimens_NNS from_IN patients_NNS suspected_VBN of_IN having_VBG mycobacterial_JJ infections_NNS 